Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim

Moleculin Biotech, Inc.

CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).
iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.
Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.
Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.